Novavax Inc NVAX shares are trading lower Tuesday after the company reported worse-than-expected financial results.
Novavax reported first-quarter revenue of $704 million, which came in below the $845.2 million estimate. The company reported quarterly earnings of $2.56 per share, which came in below the estimate of $2.69 per share, according to data from Benzinga Pro.
Novavax said the first quarter was its first profitable quarter as a commercial-stage company. The company reiterated full-year 2022 revenue guidance of $4 billion to $5 billion versus the estimate of $4.49 billion.
On the company's conference call, Novavax said it remains on track to pursue full approval of its Covid vaccine in the U.S. in the second half of 2022.
See Also: Novavax's 22% Post-Earnings Plunge: 5 Factors That Took Toll
NVAX Price Action: Novavax is making new 52-week lows on Tuesday.
The stock was down 22.1% at $41.48 at time of publication.
Photo: Jernej Furman from Flickr.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
